ANASTASIOS STATHIS

Has grant

Head of Research Service and Scientific Head Clinical Trial Unit

Istituto Cantonale di Patologia

Switzerland

Research Interests

Explore related searches

Professors in Switzerland

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Anastasios Stathis is the Head of Research Service and Scientific Head of the Clinical Trial Unit at Ente Ospedaliero Cantonale, Switzerland. His research interests encompass clinical outcomes in cancer therapies, particularly in B-cell lymphoid neoplasms and diffuse large B-cell lymphoma. Recent publications include studies on innovative treatments such as loncastuximab tesirine and tafasitamab, as well as methodologies for trial design and risk stratification in oncology.

Recent Grants

Grant: Close

BANDO DI CONCORSO PER FINANZIAMENTO DI RICERCATORI SENIOR CLINICI O DI LABORATORIO ATTIVI IN EOC

Open Date: 2023-01-01

Close Date: 2023-12-01

Articles (10)

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Collaborators (8)

Stefanie Hayoz

Head of Statistics

SWITZERLAND

View details

Giulio Sartori

Università della Svizzera Italiana (USI)

SWITZERLAND

View details

ILARIA COLOMBO

SWITZERLAND

View details

Isildinha Reis

University of Miami Health System

UNITED STATES

View details

Sara Napoli

National Institute of Oncology

SWITZERLAND

View details

John Radford

The University of Manchester

UNITED KINGDOM

View details

Gianluca GAIDANO

Professor of Hematology

ITALY

View details

ANNALISA CHIAPPELLA

Fondazione IRCCS Istituto Nazionale dei Tumori

ITALY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

ANASTASIOS STATHIS

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (10)

Clinical Outcomes of Older and Younger Patients Treated with Loncastuximab Tesirine in the LOTIS-2 Clinical Trial

PET/CT-biomarkers enable risk stratification of patients with relapsed/refractory diffuse large B-cell lymphoma enrolled in the LOTIS-2 clinical trial

IELSG30 phase 2 trial: intravenous and intrathecal CNS prophylaxis in primary testicular diffuse large B-cell lymphoma

TLD-1, a novel liposomal doxorubicin, in patients with advanced solid tumors: Dose escalation and expansion part of a multicenter open-label phase I trial (SAKK 65/16)

ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms

How to integrate CD19 specific chimeric antigen receptor T cells with other CD19 targeting agents in diffuse large B-cell lymphoma?

Tafasitamab for the treatment of patients with diffuse large B-cell lymphoma

The ATR inhibitor elimusertib exhibits anti-lymphoma activity and synergizes with the PI3K inhibitor copanlisib

In vitro anti-lymphoma activity of the first-in-class pan-NOTCH transcription inhibitor CB-103

Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022

Collaborators (8)

Stefanie Hayoz

Giulio Sartori

ILARIA COLOMBO

Isildinha Reis

Sara Napoli

John Radford

Gianluca GAIDANO

ANNALISA CHIAPPELLA

Make your next move.